Marking a major leap in diagnostic imaging, Royal Philips has secured US FDA clearance for its Spectral CT Verida system.
This paves the way for deployment of what the Netherlands company describes as the world’s first AI-powered detector-based spectral CT system in the United States.
The approval brings Philips’ next-generation imaging platform into clinical use, combining always-on spectral imaging with artificial intelligence-driven reconstruction designed to sharpen image quality, improve efficiency, and expand diagnostic insight across radiology, cardiology, and oncology.
At the core of Verida is Spectral Precise Image technology paired with a third-generation Nano-panel Precise dual-layer detector and an AI-based deep learning reconstruction engine. The system is designed to reduce image noise while enhancing clarity across CT scans, with clinicians able to adjust de-noising levels based on clinical preference.
“By combining always-on spectral imaging with AI-powered reconstruction, Verida enables clinicians to see more, first time right, supporting faster, more informed decisions and expanding the role of CT across clinical pathways," Dan Xu, Business Leader of CT at Philips, said.
The system is built on Philips’ detector-based spectral CT platform and delivers continuous spectral imaging without requiring additional scans or workflow changes. According to Philips, Verida reconstructs 145 images per second, allowing entire exams to appear in under 30 seconds—twice as fast as previous systems—and supporting throughput of up to 270 exams per day.
By capturing high- and low-energy data in a single scan, the system provides conventional and spectral imaging simultaneously, enabling more detailed tissue and material differentiation without repeat scanning or pre-selection.
“Verida incorporates Spectral Precise Image, with a third-generation Nano-panel Precise dual-layer detector with intrinsic noise reduction, along with an AI-based deep learning reconstruction engine, designed to reduce noise and enhance image quality across CT applications," the company said.
Philips says the platform is intended for use in radiology, interventional radiology, cardiology, and oncology, including treatment planning and radiation therapy preparation. It also supports head, whole-body, cardiac, and vascular imaging, and is indicated for low-dose lung cancer screening within established protocols.
The company positions Verida as part of a broader push toward AI-integrated diagnostic systems aimed at improving speed, accuracy, and clinical confidence in high-volume imaging environments.
With FDA clearance now secured, Philips is set to roll out the system in the US as hospitals continue to adopt advanced imaging technologies that promise faster workflows and deeper diagnostic insight.
_256_275.jpg)
